Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Placebo-controlled study Stories

2011-06-24 09:30:00

PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ -- The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy....

2011-06-22 06:30:00

EVANSTON, Ill., June 22, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13. GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is initially being developed as a therapy for patients who are not achieving an adequate response to their current...

2011-06-17 21:06:39

Trial found no major safety concerns; larger studies needed A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, but larger studies are needed to further investigate the safety and efficacy of etanercept. Results of this clinical trial are available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of...

2011-06-16 16:20:00

SUNRISE, Fla., June 16, 2011 /PRNewswire/ -- Bioheart, Inc. (OTC Bulletin Board: BHRT) is one of the Emerging Biotech Presenters at the International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions- July 23rd-26th in Vancouver at the Hyatt Regency Vancouver. Howard J. Leonhardt, Bioheart's Founder and Chief Technology Officer, will be presenting on Myoblast Transplantation for Heart Repair, a Review of the State of Field. His presentation will take...

2011-05-25 07:00:00

SEOUL, Korea, May 25, 2011 /PRNewswire/ -- New findings presented from pooled analyses of the STELARA® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment. Investigators also reported findings from an analysis of four placebo-controlled Phase 3 trials across patient...

2011-05-23 00:30:00

SYDNEY, May 23, 2011 /PRNewswire/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel(R) for the treatment of bacterial vaginosis (BV). Key Points: VivaGel(R) meets primary endpoint, demonstrating significant efficacy for treatment of BV VivaGel(R) expected to avoid many shortcomings of existing therapies Trial results support new patent filing which extends VivaGel(R)...

2011-05-19 04:00:00

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee. The randomized, double-blind, placebo-controlled Phase II study will evaluate the safety and efficacy of...

2011-05-16 07:01:13

(Ivanhoe Newswire) -- Pirfenidone reduces the rate of decline of lung function in patients with idiopathic pulmonary fibrosis- a condition that affects hundreds of thousands os people worldwide and will eventually kill four out of five people. In this study, patients were either given pirfenidone of a placebo for a minimum of 72 weeks. The researchers assessed the change in percentage predicted forced vital capacity (FVC) at week 72. The study showed an 8.4% decline in mean FVC in the...

2011-05-13 18:20:00

BRISBANE, Calif., May 13, 2011 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a rare and fatal lung disease affecting more than...

2011-04-19 06:00:00

Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue LUND, Sweden, April 19 /PRNewswire/ - NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM )cremophor-free IV cyclosporine formulation is used in...